May 19 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

When Genetic Data Meets Law Enforcement. The 23andMe acquisition brings to mind another recent controversy involving genetic ...